Evidence map›Paper›PMID 40196122›Full record

ReviewFrontiers in immunology2025

Pipelines for lymphocyte homeostasis maintenance during cancer immunotherapy.

Bensu Du, Jin Geng, Bin Wu, Houru Wang, Ru Luo, Hanmeng Liu, Rui Zhang, Fengping Shan, Lei Liu, Shuling Zhang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bensu Du *China Medical University, Shenyang, China.
Jin Geng *Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, China.
Bin Wu *Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Houru WangNortheast Yucai Foreign Language School, Shenyang, China.
Ru LuoJinzhou Medical University, Jinzhou, China.
Hanmeng LiuJinzhou Medical University, Jinzhou, China.
Rui ZhangChina Medical University, Shenyang, China.
Fengping ShanDepartment of Immunology, School of Basic Medical Science, China Medical University, Shenyang, China.
Lei LiuDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Shuling ZhangDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In general, increasing lymphocyte entry into tumor microenvironment (TME) and limiting their efflux will have a positive effect on the efficacy of immunotherapy. Current studies suggest maintenance lymphocyte homeostasis during cancer immunotherapy through the two pipelines tumor-associated high endothelial venules and lymphatic vessels. Tumor-associated high endothelial venules (TA-HEVs) play a key role in cancer immunotherapy through facilitating lymphocyte trafficking to the tumor. While tumor-associated lymphatic vessels, in contrast, may promote the egress of lymphocytes and restrict their function. Therefore, the two traffic control points might be potential to maintain lymphocyte homeostasis in cancer during immunotherapy. Herein, we highlight the unexpected roles of lymphocyte circulation regulated by the two gateways for through reviewing the biological characters and functions of TA-HEVs and tumor-associated lymphatic vessels in the entry, positioning and exit of lymphocyte cells in TME during anti-tumor immunity.

Indexed as

HomeostasisImmunotherapyLymphocytesLymphocytes, Tumor-InfiltratingNeoplasmsAnimalsHumansLymphatic VesselsTumor MicroenvironmentCD8 + T cellsimmunotherapylymphocytestumor-associated high endothelial venulestumor-associated lymphatic vessels

Identifiers

PMID40196122
PMCPMC11973195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.